Skip to main content
Top
Published in: Journal of Gastrointestinal Surgery 1/2020

01-01-2020 | Hepatocellular Carcinoma | 2019 SSAT Plenary Presentation

Time-to-Interventional Failure as a New Surrogate Measure for Survival Outcomes after Resection of Hepatocellular Carcinoma

Authors: Junichi Shindoh, Yusuke Kawamura, Yuta Kobayashi, Norio Akuta, Masahiro Kobayashi, Yoshiyuki Suzuki, Kenji Ikeda, Masaji Hashimoto

Published in: Journal of Gastrointestinal Surgery | Issue 1/2020

Login to get access

Abstract

Purpose

This study sought to investigate the clinical impact of repeated interventions for recurrent hepatocellular carcinoma (HCC) and to establish a new surrogate measure for survival: the time-to-interventional failure (TIF).

Methods

Based on a retrospective review of 1158 patients who underwent curative resection for HCC, the abilities of recurrence-free survival (RFS) and TIF, which was defined as the elapsed time from resection to unresectable/unablatable recurrence, to predict overall survival (OS) were compared.

Results

Within a median follow-up period of 84.9 months, 676 (59.0%) recurrence events occurred, 78.1% of which were resectable/ablatable recurrences. Of these, 99.1% of the patients underwent repeated treatments. TIF had a stronger correlation than RFS (r = 0.921 vs. r = 0.631) in prediction of OS. Patients who underwent curative-intent treatment (i.e., resection or ablation) for recurrence showed significantly better survival outcomes compared with those who underwent non-curative treatment (e.g., TACE, chemotherapy) (median OS, 89.1 months vs. 55.0 months; P < 0.0001). This tendency was constant across the AJCC stages and multivariate analysis confirmed that curative-intent treatment is associated with improved survival after initial recurrence (hazard ratio, 0.55; 95% CI, 0.37–0.81; P = 0.003).

Conclusions

OS after HCC resection is more strongly dependent on TIF than on RFS. Aggressive curative-intent interventions for recurrent HCC may prolong survival regardless of the cancer stage.
Literature
1.
go back to reference Bruix J, Sherman M, American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology. 2011 Mar;53(3):1020–2.CrossRef Bruix J, Sherman M, American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology. 2011 Mar;53(3):1020–2.CrossRef
2.
go back to reference Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, et al. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Digestive diseases. 2011;29(3):339–64.CrossRef Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, et al. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Digestive diseases. 2011;29(3):339–64.CrossRef
3.
go back to reference Belghiti J, Panis Y, Farges O, Benhamou JP, Fekete F. Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis. Ann Surg. 1991 Aug;214(2):114–7.CrossRef Belghiti J, Panis Y, Farges O, Benhamou JP, Fekete F. Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis. Ann Surg. 1991 Aug;214(2):114–7.CrossRef
4.
go back to reference Grazi GL, Ercolani G, Pierangeli F, Del Gaudio M, Cescon M, Cavallari A, et al. Improved results of liver resection for hepatocellular carcinoma on cirrhosis give the procedure added value. Ann Surg. 2001 Jul;234(1):71–8.CrossRef Grazi GL, Ercolani G, Pierangeli F, Del Gaudio M, Cescon M, Cavallari A, et al. Improved results of liver resection for hepatocellular carcinoma on cirrhosis give the procedure added value. Ann Surg. 2001 Jul;234(1):71–8.CrossRef
5.
go back to reference Imamura H, Matsuyama Y, Miyagawa Y, Ishida K, Shimada R, Miyagawa S, et al. Prognostic significance of anatomical resection and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma. Br J Surg. 1999 Aug;86(8):1032–8.CrossRef Imamura H, Matsuyama Y, Miyagawa Y, Ishida K, Shimada R, Miyagawa S, et al. Prognostic significance of anatomical resection and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma. Br J Surg. 1999 Aug;86(8):1032–8.CrossRef
6.
go back to reference Kakazu T, Makuuchi M, Kawasaki S, Miyagawa S, Hashikura Y, Kosuge T, et al. Repeat hepatic resection for recurrent hepatocellular carcinoma. Hepatogastroenterology. 1993 Aug;40(4):337–41.PubMed Kakazu T, Makuuchi M, Kawasaki S, Miyagawa S, Hashikura Y, Kosuge T, et al. Repeat hepatic resection for recurrent hepatocellular carcinoma. Hepatogastroenterology. 1993 Aug;40(4):337–41.PubMed
7.
go back to reference Nakajima Y, Ko S, Kanamura T, Nagao M, Kanehiro H, Hisanaga M, et al. Repeat liver resection for hepatocellular carcinoma. J Am Coll Surg. 2001 Mar;192(3):339–44.CrossRef Nakajima Y, Ko S, Kanamura T, Nagao M, Kanehiro H, Hisanaga M, et al. Repeat liver resection for hepatocellular carcinoma. J Am Coll Surg. 2001 Mar;192(3):339–44.CrossRef
8.
go back to reference Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg. 2002 Mar;235(3):373–82.CrossRef Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg. 2002 Mar;235(3):373–82.CrossRef
9.
go back to reference Mise Y, Hasegawa K, Shindoh J, Ishizawa T, Aoki T, Sakamoto Y, et al. The Feasibility of Third or More Repeat Hepatectomy for Recurrent Hepatocellular Carcinoma. Ann Surg. 2015 Aug;262(2):347–57.CrossRef Mise Y, Hasegawa K, Shindoh J, Ishizawa T, Aoki T, Sakamoto Y, et al. The Feasibility of Third or More Repeat Hepatectomy for Recurrent Hepatocellular Carcinoma. Ann Surg. 2015 Aug;262(2):347–57.CrossRef
10.
go back to reference Meniconi RL, Komatsu S, Perdigao F, Boelle PY, Soubrane O, Scatton O. Recurrent hepatocellular carcinoma: a Western strategy that emphasizes the impact of pathologic profile of the first resection. Surgery. 2015 Mar;157(3):454–62.CrossRef Meniconi RL, Komatsu S, Perdigao F, Boelle PY, Soubrane O, Scatton O. Recurrent hepatocellular carcinoma: a Western strategy that emphasizes the impact of pathologic profile of the first resection. Surgery. 2015 Mar;157(3):454–62.CrossRef
11.
go back to reference Yang W, Chen MH, Wang MQ, Cui M, Gao W, Wu W, et al. Combination therapy of radiofrequency ablation and transarterial chemoembolization in recurrent hepatocellular carcinoma after hepatectomy compared with single treatment. Hepatol Res. 2009 Mar;39(3):231–40.CrossRef Yang W, Chen MH, Wang MQ, Cui M, Gao W, Wu W, et al. Combination therapy of radiofrequency ablation and transarterial chemoembolization in recurrent hepatocellular carcinoma after hepatectomy compared with single treatment. Hepatol Res. 2009 Mar;39(3):231–40.CrossRef
12.
go back to reference Oba M, Hasegawa K, Matsuyama Y, Shindoh J, Mise Y, Aoki T, et al. Discrepancy between recurrence-free survival and overall survival in patients with resectable colorectal liver metastases: a potential surrogate endpoint for time to surgical failure. Ann Surg Oncol. 2014 Jun;21(6):1817–24.CrossRef Oba M, Hasegawa K, Matsuyama Y, Shindoh J, Mise Y, Aoki T, et al. Discrepancy between recurrence-free survival and overall survival in patients with resectable colorectal liver metastases: a potential surrogate endpoint for time to surgical failure. Ann Surg Oncol. 2014 Jun;21(6):1817–24.CrossRef
13.
go back to reference Makuuchi M, Kosuge T, Takayama T, Yamazaki S, Kakazu T, Miyagawa S, et al. Surgery for small liver cancers. Semin Surg Oncol. 1993 Jul-Aug;9(4):298–304.CrossRef Makuuchi M, Kosuge T, Takayama T, Yamazaki S, Kakazu T, Miyagawa S, et al. Surgery for small liver cancers. Semin Surg Oncol. 1993 Jul-Aug;9(4):298–304.CrossRef
14.
go back to reference Kobayashi Y, Kiya Y, Sugawara T, Nishioka Y, Hashimoto M, Shindoh J. Expanded Makuuchi's criteria using estimated indocyanine green clearance rate of future liver remnant as a safety limit for maximum extent of liver resection. HPB (Oxford). 2019 Jan 30. Kobayashi Y, Kiya Y, Sugawara T, Nishioka Y, Hashimoto M, Shindoh J. Expanded Makuuchi's criteria using estimated indocyanine green clearance rate of future liver remnant as a safety limit for maximum extent of liver resection. HPB (Oxford). 2019 Jan 30.
15.
go back to reference Shindoh J, Kawamura Y, Kobayashi Y, Kiya Y, Sugawara T, Akuta N, et al. Platelet-Albumin Score as a Sensitive Measure for Surgical Risk Prediction and Survival Outcomes of Patients with Hepatocellular Carcinoma. J Gastrointest Surg. 2019 Jan;23(1):76–83.CrossRef Shindoh J, Kawamura Y, Kobayashi Y, Kiya Y, Sugawara T, Akuta N, et al. Platelet-Albumin Score as a Sensitive Measure for Surgical Risk Prediction and Survival Outcomes of Patients with Hepatocellular Carcinoma. J Gastrointest Surg. 2019 Jan;23(1):76–83.CrossRef
16.
go back to reference Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017 Jul;11(4):317–70.CrossRef Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017 Jul;11(4):317–70.CrossRef
17.
go back to reference Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003 Dec 6;362(9399):1907–17.CrossRef Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003 Dec 6;362(9399):1907–17.CrossRef
18.
go back to reference Kudo M, Trevisani F, Abou-Alfa GK, Rimassa L. Hepatocellular Carcinoma: Therapeutic Guidelines and Medical Treatment. Liver Cancer. 2016 Nov;6(1):16–26.CrossRef Kudo M, Trevisani F, Abou-Alfa GK, Rimassa L. Hepatocellular Carcinoma: Therapeutic Guidelines and Medical Treatment. Liver Cancer. 2016 Nov;6(1):16–26.CrossRef
19.
go back to reference Chan AC, Poon RT, Cheung TT, Chok KS, Chan SC, Fan ST, et al. Survival analysis of re-resection versus radiofrequency ablation for intrahepatic recurrence after hepatectomy for hepatocellular carcinoma. World J Surg. 2012 Jan;36(1):151–6.CrossRef Chan AC, Poon RT, Cheung TT, Chok KS, Chan SC, Fan ST, et al. Survival analysis of re-resection versus radiofrequency ablation for intrahepatic recurrence after hepatectomy for hepatocellular carcinoma. World J Surg. 2012 Jan;36(1):151–6.CrossRef
20.
go back to reference Song KD, Lim HK, Rhim H, Lee MW, Kim YS, Lee WJ, et al. Repeated Hepatic Resection versus Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma after Hepatic Resection: A Propensity Score Matching Study. Radiology. 2015 May;275(2):599–608.CrossRef Song KD, Lim HK, Rhim H, Lee MW, Kim YS, Lee WJ, et al. Repeated Hepatic Resection versus Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma after Hepatic Resection: A Propensity Score Matching Study. Radiology. 2015 May;275(2):599–608.CrossRef
21.
go back to reference Ho CM, Lee PH, Shau WY, Ho MC, Wu YM, Hu RH. Survival in patients with recurrent hepatocellular carcinoma after primary hepatectomy: comparative effectiveness of treatment modalities. Surgery. 2012 May;151(5):700–9.CrossRef Ho CM, Lee PH, Shau WY, Ho MC, Wu YM, Hu RH. Survival in patients with recurrent hepatocellular carcinoma after primary hepatectomy: comparative effectiveness of treatment modalities. Surgery. 2012 May;151(5):700–9.CrossRef
22.
go back to reference Wang DY, Liu L, Qi XS, Su CP, Chen X, Liu X, et al. Hepatic Re-resection Versus Transarterial Chemoembolization for the Treatment of Recurrent Hepatocellular Carcinoma after Initial Resection: a Systematic Review and Meta-analysis. Asian Pac J Cancer Prev. 2015;16(13):5573–8.CrossRef Wang DY, Liu L, Qi XS, Su CP, Chen X, Liu X, et al. Hepatic Re-resection Versus Transarterial Chemoembolization for the Treatment of Recurrent Hepatocellular Carcinoma after Initial Resection: a Systematic Review and Meta-analysis. Asian Pac J Cancer Prev. 2015;16(13):5573–8.CrossRef
Metadata
Title
Time-to-Interventional Failure as a New Surrogate Measure for Survival Outcomes after Resection of Hepatocellular Carcinoma
Authors
Junichi Shindoh
Yusuke Kawamura
Yuta Kobayashi
Norio Akuta
Masahiro Kobayashi
Yoshiyuki Suzuki
Kenji Ikeda
Masaji Hashimoto
Publication date
01-01-2020
Publisher
Springer US
Published in
Journal of Gastrointestinal Surgery / Issue 1/2020
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-019-04277-y

Other articles of this Issue 1/2020

Journal of Gastrointestinal Surgery 1/2020 Go to the issue

Evidence-Based Current Surgical Practice

What’s New in the Management of Incarcerated Hernia